Although induction of apoptosis (cell death mediated by caspases) determines response to cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing agents. Furthermore, most cancers, almost by definition, are resistant to apoptosis, growth arrest and cell senescence. Then, how can anticancer agents kill cancer cell without unacceptable toxicity to a patient? The potential therapeutic approaches range from selective inhibition of antiapoptotic pathways, antiangiogenic therapy, tissue-selective therapy (including immunotherapy) to exploitation of, for example, drug resistance, oncoprotein addiction, unrestricted cell cycles, hypermitogenic and hypoxic features of cancer cells. These overlapping and complementary approaches rely on rational drug combinations (at mechanism-based doses and sequences) aimed at matching targets. To ensure killing of cancer cells selectively, we may combine apoptosis-and senescence-inducing agents with inhibitors of apoptosis (to protect normal cells), inhibitors of signal transduction with cell cycle-dependent chemotherapy, antiangiogenic agents with hypoxia-inducible factor-1 inhibitors, tissue-selective therapy with differentiating agents and activators of death receptors with chemotherapy. In theory, consecutive use of these drug combinations may control cancer.
some patients develop progressive disease despite treatment because of defects in apoptotic pathways (Mayer et al., 2003; Mueller et al., 2003) . A correlation between apoptosis and therapeutic response indicates that apoptosis, indeed, is a goal of cancer therapy (Martin and Green, 1994; Houghton, 1999; Sellers and Fisher, 1999; Spierings et al., 2003) . However, most common cancers do not easily undergo apoptosis and therefore are resistant to chemotherapy. Although apoptosis is a goal in cancer therapy, apoptosis avoidance is a hallmark of cancer.
Oncogenic (apoptosis avoidance) and nononcogenic resistance
Drug resistance is traditionally divided into intrinsic and acquired. Actually, both types of resistance are acquired: the former is acquired before therapy and the latter is caused by therapy. By mechanism, resistance can be classified as nononcogenic (due to prevention of drug-target interaction) and oncogenic (due to alterations in regulation of apoptosis and cell cycle). In nononcogenic resistance, expression of drug transporters (e.g. Pgp), metabolism of a drug and mutation of its target prevent interaction between a drug and its target. In vitro, high drug concentrations overcome nononcogenic resistance: the killing curve is simply shifted to the right ( Figure 1 ). While affording significant drug resistance, this mechanism does not render a cell malignant (Blagosklonny, 2002) .
In oncogenic resistance, in contrast, a drug interacts with its target, but downstream pathways of apoptosis and/or growth arrest are blocked. An increased drug concentration does not overcome resistance; a number of live cells have not fallen to zero (Figure 1 ). Despite DNA damage or mitotic arrest, for instance, such a cell does not undergo apoptosis. Although acquired resistance can be either nononcogenic (e.g. Pgp) or oncogenic (e.g. loss of cell cycle control and/or apoptosis), an intrinsic resistance of cancer cell is always oncogenic, otherwise a resistant cell would not be malignant. As recently reviewed (Johnstone et al., 2002; Chang et al., 2003; Garrido et al., 2003; Zhivotovsky and Orrenius, 2003) and discussed in this issue, (a) loss of caspases, (b) expression of inhibitors of apoptosis (IAP: NAIP, cIAP-1, cIAP-2, XIAP/hILP, survivin and BRUCE) and heat-shock proteins (HSP), which bind caspases and AIF, (c) oncoproteins and mitogenic kinases such as Bcl-2, BclxL, Ras, MEK, Akt and Bcr-Abl, which prevent caspase activation, all can block apoptotic pathways, thus rendering cancer cells resistant to therapy (Figure 2a ). There are two main strategies to induce apoptosis in such cancer cells. First, targeting apoptotic pathways downstream of the block (Figure 2b ) Johnstone et al., 2002; Reed, 2003) . Mitochondria-targeted therapeutics and direct caspase activators may induce apoptosis in normal cells, limiting their application as single therapeutics agents. Another approach is to reactivate apoptotic pathways, for example, by inhibiting IAPs, MEK, AKT and the NF-kB transcription factor (Orlowski and Baldwin, 2002; Blalock et al., 2003) . For example, Smac peptides, which bypass the Bcl-2 block, sensitize cancer cells to Apo-2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cytotoxic drugs (Fulda et al., 2002) . Complete eradication of established tumors and survival of mice was achieved upon combined treatment with Smac peptides and Apo-2L/TRAIL without detectable toxicity to normal tissue (Fulda et al., 2002) . In combination with inhibitors of MEK, AKT or NF-kB, chemotherapy will induce apoptosis in cancer cells (Figure 2c) . As a limitation, certain normal cells utilize the same survival pathways for protection from chemotherapy (Leverkus et al., 2003) . It may be expected that apoptosis in normal cells will limit this approach.
Apoptosis versus slow cell death
Apoptosis is usually described (but not defined) as programmed cell death (in its original meaning, the program of development of organism), cell suicide or cell death with apoptotic morphology, distinct from tissue necrosis. These descriptions are not very helpful for cancer therapy. Apoptosis is a goal of therapy, but not because we wish to avoid tumor necrosis. In cancer therapy, tissue necrosis is not an alternative to cell apoptosis ( Figure 3 ). Mechanistically, apoptosis is cell death mediated or accelerated by caspases. Why is this simple definition useful? First, by inhibiting and activating caspases (and their regulators), we can manipulate (accelerate, potentiate or block) cell death. Second, this defines the alternative form of cell death: caspase-independent or slow cell death (Figure 3 ). Note that caspases may be activated at late stages of nonapoptotic cell death, but such a late activation does not accelerate cell death (Broker et al., 2002) . Whereas apoptosis is fast and irreversible, caspase-independent death is slow. Apoptosis-reluctant cancer cells may recover ( Figure 3 , an area below slow cell death). How Figure 1 Nononcogenic and oncogenic drug resistance. Conventionally, drug resistance is measured by a drug concentration that inhibits cell growth and survival by a certain percent. For example, IC 50 is a concentration that causes 50% decrease in cell survival (e.g. in drug-sensitive cells (red line), IC 50 is 1). In nononcogenic (blue line) resistance, the dose-cytotoxicity curve is shifted to the right. An IC 50 is increased due to a failure of a drug to inhibit its target. In contrast, in oncogenic resistance, IC 50 is normal but IC 70 is not achieved. The killing curve reaches a plateau, because a drug (although normally interacts with its target) does not kill the cells Figure 3 Forms of cell death caused by anticancer drugs (cytotoxic stimuli). At low (subcytotoxic) doses, a drug (or other cytotoxic agents) can arrest cell proliferation without significant cytotoxicity. At higher drug concentrations, apoptosis-prone cells undergo rapid cell death caused by caspase activation. Apoptosisreluctant cells may either recover or undergo slow cell death. At maximal cytotoxicity, rapid necrosis may occur in any cell types Pepper et al., 2003) . For example, UCN-01 and flavopiridol induce apoptosis and growth arrest, in high and low concentrations, respectively (Grant and Dent, 2002) . But most importantly, the ability of cells to undergo apoptosis is an intrinsic property of a cell. Simplifying, drugs induce apoptosis in apoptosis-prone cells. For example, in Jurkat leukemia cells, paclitaxel (PTX) induces mitotic arrest and activates caspases-8, -9 and -3, causing apoptosis (Goncalves et al., 2000; . In contrast, PTX does not activate caspases in many cancer cell lines, such as breast cancer cell lines (Merlin et al., 2000; Abal et al., 2003) . A typical dose-response (cytotoxicity) curve is shown in Figure 4 . According to the IC 50 (a conventional measure of drug resistance), MDA-MB-231 breast cancer cells are seemingly more sensitive than Jurkat cells. However, unlike Jurkat cells, MDA-MB-231 cells do not die. They exit mitosis (without cell division) and form multinucleated cells . These large cells remained metabolically active and attached to the plastic . Furthermore, normal arterial smooth muscle cells can tolerate PTX for several weeks without apoptosis. Thus, both normal and cancer cells can be either apoptosis prone or apoptosis reluctant.
Inhibition of caspases: from apoptotic to slow death
In apoptosis-prone cells, anticancer drugs activate the intrinsic mitochondrial pathway, caspase-9 and -3 Brenner et al., 2003) . Many drugs simultaneously activate caspase-8 (Fulda et al., 2001; Akay and Gazitt, 2003) . Furthermore, a cytotoxic drug can activate alternative apoptotic pathways, depending on cell type (Fulda et al., 2001) . In apoptosis-prone cells, caspase inhibitors (Z-VAD-fmk), Bcl-2, BclxL and BcrAbl convert apoptosis to slow cell death, prolonging cell survival (Ibrado et al., 1997; Panvichian et al., 1998; Sane and Bertrand, 1999; Goncalves et al., 2000; Perkins et al., 2000; . In contrast, these inhibitors do not affect apoptosis-reluctant cells; neither inhibitors of caspases nor Bcl-2 can further delay slow cell death . Vice versa, reactivation of apoptotic pathways (by abolishing antiapoptotic NFkB, Bcr-Abl, IAPs) converts slow cell death to apoptosis.
Reactivation of apoptotic cascade in apoptosis-reluctant cancer cells
In apoptosis-reluctant cells, a reactivation of apoptotic pathways renders cells apoptosis prone. Then, cytotoxic stimuli will cause apoptosis ( Figure 2c intrinsic (caspase-9) pathways, which both convert on caspase-3, can potentiate each other (Milner et al., 2002) . TNF, FasL, TRAIL (activators of capsase-8) potentiate DNA-damaging drugs, which induce mitochondrial release of inhibitors of IAP to reactivate caspase-3. This, in turn, sensitizes cells to TRAIL (Leverkus et al., 2003) . The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAILmediated apoptosis by reducing levels of c-FLIP (Sayers et al., 2003) . 4. Synergistic combinations may include two agents with multiple and partially opposite mechanisms of actions and several signal transduction inhibitors (Grant and Dent, 2002; Jin et al., 2002 Jin et al., , 2003 . In such a combination, one drug can be considered as an apoptosis sensitizer and another as a cytotoxic drug. In brief, there are myriad synergistic combinations of numerous drugs with diverse and multiple mechanisms of action. Furthermore, the mechanism of synergy of a particular drug combination can vary in different cell lines (Fulda et al., 2001) . The complexity of the field requires to substitute a myriad of facts with a few simplifying principles.
Principles of synergy
In a synergistic combination, one drug abrogates an antiapoptotic block, allowing another drug to activate Strategies to enforce cell death in cancer MV Blagosklonny the corresponding apoptotic pathway ( Figure 2c ). In some cases, inhibitors of apoptosis (NF-kB, PI-3K, cAIP, FLIP) are constantly expressed and active in cancer cells, and a drug alone cannot transduce the apoptotic signal beyond this block, unless another drug release the block. In other cases, a downstream antiapoptotic block is induced by an agent itself (Solary et al., 2000) . For example, TNF and PMA activate NFkB, which in turn blocks apoptosis (Beg and Baltimore, 1996; Wang et al., 1998) . DNA-damaging and microtubule-active drugs stimulate mitogen-activated pathways, diminishing their own cytotoxicity (Solary et al., 2000) . However, in synergistic combinations, one drug re-establish pathways that are necessary for apoptosis caused by another drug. In other words, one drug renders an apoptosis-reluctant cell apoptosis prone. Then, another drug induces apoptosis. A second mechanism of synergy involves cyclotherapeutic agents, which kill cells in a particular phase of the cell cycle (Dixon and Norbury, 2002) . For example, topoisomerase I inhibitors (e.g. camptothetin) and mitotic poisons (e.g. PTX) kill cells predominantly in S phase and mitosis, respectively. By arresting certain cells in G1, these drugs antagonize themselves (Giannakakou et al., 2001; Wang et al., 2002) . Then abrogators of cell cycle checkpoints (e.g. UCN-01) can potentiate these cyclotherapeutic agents (Monks et al., 2000) . Therefore, abrogators of G1 and G2 checkpoints and cyclotherapeutic agents may be synergistic (Shao et al., 1997; Mack et al., 2003) .
Principles of antagonism
On the other hand, a typical antagonistic combination also involves a cyclotherapeutic agent. By inducing growth arrest, another agent can antagonize a cyclotherapeutic drug (Shah and Schwartz, 2001 ). This antagonism is usually sequence dependent. For example, PTX, a highly cyclo-dependent drug, which preferentially kills cells in mitosis, whereas flavopiridol arrests cells in interphase, preventing mitosis. Not surprisingly that pretreatment with flavopiridol prevents PTX effects. When added after PTX, flavipiridol potentiates apoptosis in mitotic cells (Motwani et al., 1999) . It is important that at low doses flavopiridol may arrest normal cells and low-aggressive cancer cells but not most aggressive cancer cells, thus not antagonizing PTX in the latter (Pardee, 2002) .
Unwanted synergy in normal cells: side effects
Combinations of signal transduction inhibitors and chemotherapy can be synergistic. So far, synergy (a supra-additive effect) was considered as a goal of drug combinations. It should be kept in mind, however, that synergistic drug combinations might be synergistically toxic to a patient due to synergy in normal cells. For example, proteasome inhibition results in TRAIL sensitization of normal keratinocytes by removing the resistance-mediating block of caspases (Leverkus et al., 2003) . To ensure cancer cell death, drug combinations should potentiate apoptosis in cancer cells selectively. It does not matter if a combination is synergistic, merely additive or even less than additive in cancer cells, as long as it is less than additive or even antagonistic, in normal cells. For example, TRAIL in combination with doxorubicin (DOX) selectively may kill malignant but not normal prostate cells (Voelkel-Johnson, 2003) . Otherwise, synergy in vitro may be translated into side effects in the clinic. Although Iressa (an inhibitor of the EGF receptor) and chemotherapy are synergistic in vitro, there was no matching therapeutic benefit in patients (Wilkinson, 2002; Dancey and Freidlin, 2003) . Synergistic (in vitro) drug combinations often show no clinical benefit and may increase side effects (Winegarden et al., 2003) . For example, synergy between TNF and chemotherapy results in side effects. For example, endogenous TNF may mediate cisplatin-induced nephrotoxicity. Bleomycin-induced pulmonary fibrosis is another example of a toxic effect linked to TNF (Szlosarek and Balkwill, 2003) .
Selective potentiation: cyclotherapy
Is it possible to design drug combinations that are synergistic in cancer and antagonistic in normal cells? Paradoxically, a drug combination can be predominantly cytotoxic to cancer cells, precisely because cancer cells are resistant to growth arrest. For example, 17-allylaminogeldanamycin (17-AAG) downregulates Akt and, therefore, sensitizes Akt-expressing breast cancer cells to PTX (Solit et al., 2003) . In contrast, by arresting normal cells (and certain cancer cells), an inhibitor of signal transduction (e.g. 17-AAG) would be expected to antagonize PTX.
Hallmarks of cancer include: (a) apoptosis avoidance (in part due to antiapoptotic and mitogenic kinases) and (b) autonomous growth, independent of mitogens and resistant to antimitogens. This provides a means for cyclotherapy (Blagosklonny and Darzynkiewicz, 2002) . According to this potential strategy, for instance, one drug (modulator, Figure 5 ) inhibits kinases such as ErbB, MEK, PI-3K and Raf-1. This renders a cancer cell sensitive to apoptosis ( Figure 5 ). The same drug arrests normal cells cycle, but not an autonomous cancer cell (e.g. Bishop et al., 2002) . A cyclotherapeutic drug will then kill cancer cells, without affecting normal cells. A combination of cytostatic and cyclotherapeutic agents can ensure death of cancer cells selectively.
Selective antagonism in normal cells
To protect normal cells, a rational drug combination should be selectively antagonistic. For example, a combination of an apoptosis-inducing drug (e.g. flavopirodol) with a caspase inhibitor (e.g. Z-DEVD-fmk) is very antagonistic. For example, in parental HL60 cells, Z-DEVD-fmk blocks apoptosis caused by flavopiridol. Yet, Z-DEVD-fmk does not antagonize flavopiridol in multidrug-resistant leukemia cells that express MRP or PgP (Blagosklonny, 2003b) . These cells pump Z-DEVDfmk out (these cells do not pump flavopiridol out). Therefore, a combination of Z-DEVD-fmk and flavopiridol was not antagonistic in multidrug-resistant HL60 cells (Blagosklonny, 2003b) . Inhibitors of apoptosis can be used in drug combinations to protect certain normal cells selectively, when cancer cells either pump these inhibitors out (MDR cancer cells) or are apoptosisreluctant anyway. Also, inhibitors of apoptosis can be used for protection of some normal cells against cytotoxic drugs, when such drugs are intended to induce senescence in cancer cells.
Induction of cancer cell senescence
Like apoptosis, cell senescence or replicative cell death had been initially described morphologically: a large cell shape, high metabolic activity and beta-galactosidase expression. By mechanism, senescence is a result of hypermitogenic cell cycle arrest (Blagosklonny, 2003a) . In contrast to quiescence (G 0 ), which caused by mitogen withdrawal, senescence can be caused by mitogen overstimulation and cell cycle arrest in the late G1 and G2 phases, without necessarily inhibiting cell growth in size. In this view, hypermitogenic arrest is simultaneous mitogen stimulation and downstream inhibition of CDKs. For example, activated Ras and Raf-1 via mitogen-activated pathways induce CDK inhibitors p16, p21 and p57. Thus, overactivated Raf-1 and Ras simultaneously stimulate growth/survival and block CDKs by inducing CDK inhibitors. Similarly, a telomere shortening causes accumulation of p21 and other CDK inhibitors, resulting in cell senescence.
Cell immortality is a hallmark of cancer. Then, how can possibly anticancer drugs not only induce senescence in cancer cells but also induce it preferentially in cancer cells? The notion of senescence as hypermitogenic cell cycle arrest gives an answer. Cancer cells, with overactivated mitogenic pathways, may be inclined to hypermitogenic arrest and senescence. First, phorbol ester (PMA), which activates the PKC/MAPK pathway, arrests cell cycle in certain leukemia and cancer cell lines. PMA is undergoing clinical trials in the therapy of leukemia (Strair et al., 2002) . Also, PMA-induced growth arrest can be transformed to apoptosis (Blagosklonny, 1998; Grant and Dent, 2002) . Second, most chemotherapeutic agents arrest cell cycle, not inhibiting mitogenic pathways (see Blagosklonny, 2003a) . In cancer cells, induction of senescence can be detectable even at the lowest drug doses that had a measurable growth-inhibitory effect (Schmitt et al., 2002; Roninson, 2003) . DOX, cisplatin, hydroxyurea, camptothecin or bromodeoxyuridine, as well as microtubule-active drugs can induce senescence (Roninson, 2003 ). Yet, these drugs are routinely used in cancer therapy. Should different schedules be used? Or lower doses for a longer time? Or combinations with phorbol ester? Or combinations with caspase inhibitors to avoid apoptosis in normal cells? At present, there is no answer.
Antiangiogenic therapy
Tumor growth is dependent on angiogenesis. Therefore, inhibition of endothelial cells (antiangiogenic therapy) is expected to inhibit cancer growth (Folkman, 1971; Harris, 2002; Kerbel and Folkman, 2002) . Furthermore, low doses of conventional anticancer drugs can inhibit angiogenesis. Unlike cancer cells, which acquire resistance to therapy, endothelial cells will not easily acquire mutations to confirm drug resistance (Kerbel, 1997; Klement et al., 2002) . However, cancer cell can acquire resistance to hypoxia (Graeber et al., 1996) , and hence to antiangiogenic therapy (Yu et al., 2002) . Hypoxia selects for apoptosis-resistant and highly malignant cells (Graeber et al., 1996; Kim et al., 1997) . Also, hypoxia 'activates' cancer cells. Under hypoxia, hypoxia-inducible factor (HIF)-1 is stabilized and transactivates hundreds of genes, including growth factors and their receptors, glycolitic enzymes and extracellular proteases, thus stimulating cell survival, invasion, metastasis and angiogenesis (Semenza, 2002) . Such a compensatory hypoxic response may hamper antiangiogenic therapy (Figure 6a ). In addition, it was suggested that antiangiogenic therapy via induction of HIF may promote metastasis, tumor invasion and progression (Panvichian et al., 1998; Krishnamachary et al., 2003; Staller et al., 2003) . Ideally, antiangiogenic therapy should be combined with inhibitors of HIF-1, thus preventing compensatory responses (Blagosklonny, 2001; Harris, 2002; Semenza, 2003) . Furthermore, inhibitors of HIF-1 are a mechanism-based antiangiogenic therapy, because it is Figure 5 Cyclotherapy. Initially, a normal cell is apoptosis prone, whereas a cancer cell is apoptosis reluctant and resistant to cyclotherapeutic agent. A modulator such as a kinase inhibitor reverses resistance of cancer cells (see Figure 2c) . Simultaneously, cells with normal cell cycle control are arrested by the same modulator and therefore 'escape' a cyclotherapeutic agent the HIF-mediated response that drives a tumor angiogenesis in the first place. Inhibitors of HIF-1 are currently under development (Giaccia et al., 2003; Semenza, 2003) .
Instead of inflicting 'hypoxia', an effective antiangiogenic therapy in combinations with anti-HIF agents will cause deep hypoxia or anoxia (Figure 6b) . Anoxia, in turn, is associated with low glucose, starving cells to death. In the absence of defensive HIF-1 expression, anoxia and nutrient deficiency will result in tissue necrosis; no tumor cell can be resistant to tissue necrosis. To further exploit hypoxia, antiangiogenic therapy could be combined with prodrugs, which are activated in hypoxic cells (Brown and Giaccia, 1998) . Alternatively, instead of targeting HIF-1, we can exploit its high activity (McCarty, 2003) .
A cancer specific target and the magic bullet
For many years, the main scientific effort was to identify targets that are specific and vital for a cancer cell. In fact, one such a target has been identified and an active drug had been developed. The target is Bcr-Abl and the drug is Gleevec (Druker, 2002; Sawyers, 2002) . Bcr-Abl, a product of a chromosomal translocation (e.g. Philadelphia chromosome), is specific and vital for leukemia. Bcr-Abl blocks apoptosis by inhibiting caspases (Amarante-Mendes et al., 1998; Sattlermc and Griffin, 2003) . Since most anticancer drugs act upstream of the Bcr-Abl block (Figure 2a) , Bcr-Abl-expressing cells are resistant to apoptosis caused by anticancer agents, including DNA-damaging and microtubule-active drugs Skorski, 2002) . Proapoptotic stimuli may accumulate upstream of the Bcr-Abl block. In the presence of Bcr-Abl, other inhibitors of apoptosis become redundant. For example, Bcl-2 is downregulated, because it is substituted for by BclxL, which is induced by Bcr-Abl (Amarante-Mendes et al., 1998). When the Bcr-Abl block is suddenly removed, the apoptotic cascade will be activated (Figure 2c) . Thus, Gleevec, which inhibits Bcr-Abl, induces apoptosis in Bcr-Abl-expressing leukemia cells. Successful treatment of Bcr-Abl-expressing leukemia with Gleevec (imatinib, STI571) is the most spectacular achievement in oncology (Druker, 2002; Sawyers, 2002) . Since Gleevec also inhibits the PDGF receptor and c-kit, it causes side effects (Ebnoether et al., 2002) . Thus, side effects result from Gleevec's nonselectivity, even though Bcr-Abl is absolutely leukemia specific. On the other hand, due to its nonselectivity, Gleevec is used for the therapy of ckit-expressing gastrointestinal stromal tumors and PDGF receptor-dependent malignancies (George, 2003; von Mehren, 2003) .
Other highly specific targets include the PML-RAR alpha fusion protein and the mutant FLT3 kinase in acute promyelocytic leukemia and myeloid leukemia (Levis et al., 2002; Sohal et al., 2003) . Like many oncogenic kinases, FLT3 is a client of Hsp90 and inhibitors of Hsp90 may be useful for the therapy of leukemia (Yao et al., 2003) . Inhibitors of Hsp90 such as geldanamycin and 17-AAG reduce levels of several signal transduction proteins including Bcr-Abl, FLT3 and c-kit (Fumo et al., 2003; Yao et al., 2003) . The depletion of Hsp90 client proteins correlates with cytostatic effects of geldanamycin and its analogs . Although Hsp90 is not cancer-specific target, inhibitors of Hsp90 are predominantly toxic for cells that express Bcr-Abl, mutated FLT3 or Kit Fumo et al., 2003) .
Neither a target nor a drug must be absolutely cancer specific and target selective, respectively. Although many anticancer targets have been suggested and the inhibition of these targets causes antitumor effects, it should be explicitly stated that they are not cancer specific. Currently, Bcr-Abl is a sole example of cancerspecific target for a magic bullet, even though the current bullet is not selective.
Tissue-selective therapy
There are some other highly specific targets, which are often considered as cancer specific. For example, antihormonal therapies for breast and prostate cancer as well as immunotherapy aimed at tumor-derived antigens are highly selective. Ironically, cancer-specific targets for immunotherapy such as the melanomaderived protein turned out to be a normal (melanocyte-differentiation) antigen (Overwijk and Restifo, 2000) . So, it is not a cancer-specific protein, which is absent in normal cells, but a tissue-specific protein that is shared by both normal and malignant melanocytes. Malignant melanocytes tend to lose tissue-specific proteins (dedifferentiation) rather than to acquire them. Even further, tissue-selective therapy will preferentially attack normal melanocytes, sparing undifferentiated cancer cells.
Let us start from the beginning. The standard therapy of cancer is limited by its toxicity to normal cells (side effects). Logically, the goal of anticancer therapy is to exploit the differences between normal and cancer cells. Instead of discriminating cancer and normal cells, it may be easier to exploit peculiarities of normal tissues: incorporation of iodine by thyroid or dependence on androgens, estrogens and thyroid-stimulating hormone (TSH) for prostate, breast, and thyroid tissues, respectively (Blagosklonny, 2003c) . As another example, glucocorticoids inhibit proliferation and induce apoptosis in normal lymphocytes and, therefore, are effective against malignant lymphoid cells.
Targeting nonessential tissues (e.g. breast and prostate) results in few side effects. Furthermore, targeting essential tissues (e.g. lymphocytes) is possible, although tissue-specific side effects are expected (e.g. immunosuppression). Targeting a subtissue instead of an entire tissue will decrease side effects (Blagosklonny, 2003c) .
A tissue-specific therapy is aimed at 'something' unique for a particular tissue. The uptake of radioactive iodine, a normal function of thyroid cells, allows its accumulation 2000 folds over serum levels, thus killing the thyroid cell selectively. The prognosis of patients with papillary, the most differentiated thyroid cancer, is favorable and depends on tumor differentiation and the ability to take up radioactive iodine. A cure rate of radioiodine therapy (after 12 years) is 65% in papillary cancer (Pelikan et al., 1997) . Lacking thyroid-specific functions, dedifferentiated tumors are inaccessible to standard therapeutic procedures such as radioiodide therapy and TSH suppression. In one-third of the cases following TSH-suppressive or radioiodine therapy, dedifferentiation is observed giving rise to tumors that are refractory to conventional treatment. Eventually, this may lead to the most malignant human tumor (anaplastic thyroid carcinoma) with a life expectancy of only a few months. Logically, tissue-specific therapy and differentiating therapy complement each other. By reactivating tissue-specific genes, a differentiating therapy provides a target for tissue-specific therapy. There are hopes that retinoic acid and other agents may induce differentiation in thyroid cancer (Simon et al., 2002) . Alternatively, recombinant TSH can induce the uptake of high-dose 131 iodine to ablate thyroid tissue (Berg et al., 2002) .
As another example, normal prostate epithelial and testicular cells selectively depend on androgens for survival and proliferation. Antiandrogen therapy causes regression of prostate tumors in more than 80% of patients with metastatic disease (Reese, 2000) . By killing cancer cells having a tissue-specific characteristic (e.g. hormone dependence), tissue-selective therapy not only causes remission but also selects for resistant cancer. Once a relapse occurs following primary endocrine treatment, metastatic prostate cancer is one of the most therapy-resistant human neoplasms.
Selection for drug resistance: hallmark of effective therapy
The Bcr-Abl inhibitor Gleevec selects for resistance exactly because it is selective and effective against BcrAbl-expressing leukemia. By killing all leukemia cells that depend on Bcr-Abl, it selects for cells with mutant or amplified Bcr-Abl and cells with additional oncogenic mutations (Daley, 2003; Druker, 2002; Sawyers, 2002) . As another example, tissue-selective therapies of prostate and thyroid cancers with antiandrogens and radioactive iodine, respectively, are very selective and effective, causing clinical responses and remissions. These effective therapies eventually select for drug resistance, associated with tumor progression (Blagosklonny, 2003c ). Development of resistance, which is accompanied by dedifferentiation, is an inherent limitation of tissue-selective therapy. Once relapsed, such cancer is resistant and aggressive.
It should be expected that antiangiogenic therapy, if effective, will favor selection for cells with overexpressed HIF-1, which are resistant to hypoxia and apoptosis and highly aggressive. Acquiring of drug resistance is a hallmark of any selective and effective therapies, including antibiotics for bacterial infections. Despite this 'obstacle', antibiotics and Gleevec are very useful in the therapy of bacterial infections and leukemia.
Exploiting resistance
Selection for resistance is not only unavoidable process but also can be exploited for selective anticancer therapy. As we discussed, multidrug-resistant cancer cells can pump out pharmacologic inhibitors of apoptosis, allowing apoptosis-inducing drugs to kill such cells selectively (Blagosklonny, 2003b) . Similarly, pretreatment with low doses of DOX arrest cells in G2 and thus can prevent cell death caused by epothilone B, a mitotic poison. DOX protects nonresistant cells but not resistant cells, which pumps DOX out (Blagosklonny, 2003b) . It is worth noting that not only nononcogenic resistance but also oncogenic resistance can be exploited. Like cells expressing Pgp/MRP, cell lacking wt p53 are resistant to low doses of DOX. Pretreatment with low doses of DOX prevents toxicity of microtubule-active drugs in normal but not in wt p53-deficient cells. In general, resistance to growth arrest is a basis for selective drug combinations aimed at matching targets. These different views on the same problem illuminate that the solution is drug combinations.
Conclusion
With few exceptions (e.g. Bcr-Abl), cancers lack targets that are simultaneously specific and vital. There are plenty of vital targets such as DNA and microtubules, for instance. However, they are not specific for cancer. Novel targets such as HDAC, the proteasome and HSP90 are also needed to all normal cells. There are of course specific alterations in cancer cells. These include loss of targets such as wt p53 and Rb (rendering cells resistant to growth arrest), activation of redundant mitogenic signaling pathways (rendering cells resistant to growth arrest) and acquiring of Pgp in certain drug resistant cancers. By taking different perspective, it all comes together. In the absence of a single specific and essential anticancer drug target, selective anticancer effect can be achieved by hitting not one but at least two targets. Matching selective and essential targets, a drug combinations can be both selective and effective (Blagosklonny et al., 2003d) .
Similarly, tissue-selective drugs complement differentiating agents. Antiendothelial therapy complement anti-HIF therapy. Inhibitors of normal cell cycles complement cyclotherapeutic agents. We can view potential strategies more than one way. An endothelial cell is a vital and relatively specific target, which is merely located outside a cancer cell. As a target, an endothelial cell is matched by HIF-1, a selective target in hypoxic tumors. Rational drug combinations that target matching (specific and vital) targets may kill cancer cells selectively.
